Navigation Links
Halozyme Therapeutics and Eisai to present data evaluating the antitumor effects of PEGPH20 in combination with eribulin mesylate in preclinical breast cancer models
Date:12/9/2015

SAN DIEGO and WOODCLIFF LAKE, N.J., Dec. 9, 2015 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) and Eisai Inc. will present a scientific poster entitled, "Pegylated Recombinant Human Hyaluronidase PH20 (PEGPH20) Enhances Efficacy of Eribulin Mesylate (HALAVEN®) in Triple Negative Breast Cancer Xenografts" at the 38th Annual San Antonio Breast Cancer Symposium (SABCS) on Dec. 9. 

The research showed the potential impact for PEGPH20-mediated hyaluronan (HA) removal on concentrations of eribulin and antitumor effects of breast cancer therapy in preclinical models. Halozyme's investigational new candidate drug, PEGPH20 targets the degradation of HA, a glycosaminoglycan or chain of natural sugars that may accumulate in certain tumors.

Halozyme, a biotechnology company developing novel oncology and drug-delivery therapies, and Eisai Co., Ltd., the parent company of Eisai Inc., announced a clinical collaboration in July 2015, with plans to initiate a phase 1b/2 clinical trial to evaluate PEGPH20 plus eribulin in first-line HER2-negative metastatic breast cancer patients with high-HA tumors.

"Our preclinical studies have revealed important data about the potential for PEGPH20 when used in combination of eribulin, and we are looking forward to expanding on these important preclinical findings when we initiate our clinical study with Eisai," said Dr. Helen Torley, president and CEO of Halozyme. "We remain encouraged by the potential for PEGPH20 to help patients across a range of cancer and therapy types. Our presentation today reflects the growing body of research supporting this potential of PEGPH20."

"Data presented today highlight a productive preclinical collaboration with Halozyme and support Eisai's commitment to address the unmet medical needs of patients with advanced breast cancer," said Alton Kremer, Deputy President, Oncology PCU and Chief Medical Officer, Global Oncology Business Unit, Eisai Inc. "We are encouraged by these preclinical data and look forward to enrolling patients in the clinical trial early next year."

SABCS Poster Presentation Details:

Poster Session:
P1-03-09, Wednesday, Dec. 9, 5:00 p.m. CT

About Eribulin Mesylate Injection (Available as HALAVEN® in the United States)
The above publication does not necessarily contain information that is consistent with the U.S. prescribing information for HALAVEN® (eribulin mesylate). It is an investigational use and there is no guarantee that this use will become available commercially.

HALAVEN® (eribulin mesylate) injection is indicated for patients with metastatic breast cancer who have received at least two chemotherapeutic regimens for the treatment of metastatic breast cancer. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting. Eribulin is a synthetic analog of halichondrin B, a natural product that was isolated from the marine sponge Halichondria okadai. First in the halichondrin class, eribulin is a microtubule dynamics inhibitor with a distinct binding profile. Based on in vitro studies, eribulin exerts its effect via a tubulin-based antimitotic mechanism ultimately leading to apoptotic cell death after prolonged and irreversible mitotic blockage.

Important Safety Information
Neutropenia

  • Monitor complete blood counts prior to each dose, and increase the frequency of monitoring in patients who develop Grade 3 or 4 cytopenias. Delay administration and reduce subsequent doses in patients who experience febrile neutropenia or Grade 4 neutropenia lasting longer than 7 days
  • Severe neutropenia (ANC <500/mm3) lasting more than 1 week occurred in 12% (62/503) of patients. Patients with elevated liver enzymes >3 × ULN and bilirubin >1.5 × ULN experienced a higher incidence of Grade 4 neutropenia and febrile neutropenia than patients with normal levels
  • Grade 3 and Grade 4 neutropenia occurred in 28% and 29%, respectively, of patients who received eribulin. Febrile neutropenia occurred in 5% of patients and two patients (0.4%) died from complications
  • Peripheral Neuropathy

  • Patients should be monitored closely for signs of peripheral motor and sensory neuropathy
  • Grade 3 peripheral neuropathy occurred in 8% of patients, and Grade 4 in 0.4% of patients who received eribulin. Delay administration of eribulin until resolution to Grade 2 or less
  • Neuropathy lasting more than 1 year occurred in 5% of patients. Twenty-two percent of patients developed a new or worsening neuropathy that had not recovered within a median follow-up duration of 269 days (range 25-662 days)
  • Peripheral neuropathy (5%) was the most common adverse reaction resulting in discontinuation
  • Pregnancy Category D

  • Eribulin is expected to cause fetal harm when administered to a pregnant woman and patients should be advised of these risks 
  • QT Prolongation

  • In an uncontrolled ECG study in 26 patients, QT prolongation was observed on Day 8, independent of eribulin concentration, with no prolongation on Day 1. ECG monitoring is recommended for patients with congestive heart failure; bradyarrhythmias; concomitant use of drugs that prolong QT interval, including Class Ia and III antiarrhythmics; and electrolyte abnormalities
  • Correct hypokalemia or hypomagnesemia prior to initiating eribulin and monitor electrolytes periodically during therapy. Avoid in patients with congenital long QT syndrome
  • Hepatic and Renal Impairment

  • For patients with mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic and/or moderate or severe (CrCl 15-49 mL/min) renal impairment, a reduction in starting dose is recommended
  • Most Common Adverse Reactions

  • Most common adverse reactions (>25%) reported in patients receiving eribulin were neutropenia (82%), anemia (58%), asthenia/fatigue (54%), alopecia (45%), peripheral neuropathy (35%), nausea (35%), and constipation (25%)
  • The most common serious adverse reactions reported in patients receiving eribulin were febrile neutropenia (4%) and neutropenia (2%)
  • For more information about HALAVEN®, click here for the full Prescribing Information.

    About Halozyme
    Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies that target the tumor microenvironment. Halozyme's lead proprietary program, investigational drug PEGPH20, applies a unique approach to targeting solid tumors, allowing increased access of co-administered cancer drug therapies to the tumor. PEGPH20 is currently in development for metastatic pancreatic cancer, non-small cell lung cancer, gastric cancer, metastatic breast cancer and has potential across additional cancers in combination with different types of cancer therapies. In addition to its proprietary product portfolio, Halozyme has established value-driving partnerships with leading pharmaceutical companies including Roche, Baxalta, Pfizer, Janssen and AbbVie for its drug delivery platform, ENHANZE™, which enables biologics and small molecule compounds that are currently administered intravenously to be delivered subcutaneously. Halozyme is headquartered in San Diego. For more information visit www.halozyme.com.

    About Eisai Co., Ltd. 
    Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With over 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including oncology and neurology.

    As a global pharmaceutical company, our mission extends to patients around the world through our investment and participation in partnership-based initiatives to improve access to medicines in developing and emerging countries. For more information about Eisai Co., Ltd., please visit www.eisai.com.

    About Eisai Inc.
    At Eisai Inc., human health care is our goal. We give our first thoughts to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to help address unmet medical needs. We are a fully integrated pharmaceutical business with discovery, clinical, manufacturing and marketing capabilities. Our key areas of commercial focus include oncology and specialty care (Alzheimer's disease, epilepsy and metabolic disorders). To learn more about Eisai Inc., please visit us at www.eisai.com/US.

    Eisai Inc. has affiliates that are part of a global product creation organization that includes R&D facilities in Massachusetts, New Jersey and Pennsylvania, as well as a global demand chain organization that includes facilities in Maryland and North Carolina. Eisai's global areas of R&D focus include neuroscience; oncology; metabolic disorders; vascular, inflammatory and immunological reaction; and antibody-based programs.

    Safe Harbor Statement
    In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning the possible activity, benefits and attributes of PEGPH20, the possible method of action of PEGPH20, its potential application to improve cancer therapies and statements concerning future actions relating to the development of PEGPH20) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are typically, but not always, identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including unexpected expenditures and costs, unexpected results or delays in development of product candidates and regulatory review, regulatory approval requirements, unexpected adverse events and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the Halozyme Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2015.Media Inquiries: Halozyme Therapeutics, Inc.Eisai Inc.Jim Mazzola

    Patricia Councill858-704-8122

    201-746-2139ir@halozyme.com

    Patricia_Councill@Eisai.comInvestor Inquiries:Eisai Inc.Alex Scott201-746-2177

     

     

    Logo - http://photos.prnewswire.com/prnh/20100302/LA63139LOGO
    Logo - http://photos.prnewswire.com/prnh/20151208/294446LOGO

     


    '/>"/>
    SOURCE Halozyme Therapeutics, Inc.; Eisai Inc.
    Copyright©2015 PR Newswire.
    All rights reserved


    Related medicine technology :

    1. Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer
    2. Halozymes Phase 1b Clinical Trial Of PEGPH20 With Gemcitabine Indicates Positive Activity Against Pancreatic Cancer
    3. Halozyme to Host Second Quarter 2013 Financial Results Conference Call
    4. Halozyme Provides Update on ViroPharma Phase 2 Trial of Subcutaneous Cinryze (C1 Esterase Inhibitor [Human]) Formulation with rHuPH20
    5. Halozyme Reports Second Quarter 2013 Financial Results
    6. Halozyme Announces Roche Receives Marketing Authorization for Herceptin SC in European Union
    7. Halozyme to Present New Data on PEGPH20 in Pancreatic Cancer at European Cancer Congress
    8. Halozyme Therapeutics To Present At The BioCentury Newsmakers In The Biotech Industry Conference
    9. Commercial Launch of Herceptin SC in EU Triggers Milestone Payment to Halozyme from Roche
    10. Halozyme Presents PEGPH20 Phase 1b Clinical Trial Data at European Cancer Congress 2013
    11. SWOG Initiates Randomized Phase 2 Clinical Trial of Halozymes PEGPH20 in Combination with modified FOLFIRINOX for Advanced Pancreatic Cancer
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/28/2020)... GILBERT, Ariz. (PRWEB) , ... January 28, 2020 ... ... to satisfy cravings, manage hunger, and stay energized while making healthy changes, ... snack that’s designed to tackle hunger between meals. The global health and wellness ...
    (Date:1/27/2020)... ... January 27, 2020 , ... ... three-day intense hands-on experience with live patients in Santo Domingo, Dominican Republic. The ... Dr. Arun K. Garg. Drs. Nash routinely perform surgery for dental implants ...
    (Date:1/27/2020)... GRANTS PASS, Ore. (PRWEB) , ... January 27, ... ... Dame Dr. Effie Chow, Ph.D., International Qigong Grand Master, founder of Global Healing ... Dr. Effie Chow, Ph.D, born on September 28th, the same day as Confucious, ...
    Breaking Medicine Technology:
    (Date:1/28/2020)... ... January 28, 2020 , ... Perimeter ... CEO of Perimeter Behavioral Hospital of Springfield. Mr. Lemke possesses more than 30 ... in different organizations in the mental healthcare value chain. , Prior to his ...
    (Date:1/27/2020)... ... January 27, 2020 , ... Controlled Contamination Services is pleased to ... Regions. As Vice President of the East/Central Regions, she will be responsible for all ... with CCS since 2015 and has been an integral part of the company’s success ...
    (Date:1/27/2020)... , ... January 27, 2020 , ... More than 200 ... Stimulation at Kessler Foundation in West Orange on January 24. , ... with paralysis, occupies an 11,000 sq. ft. addition to the West Orange Campus shared ...
    (Date:1/25/2020)... , ... January 25, 2020 , ... Trust must be ... many people are unwilling to place their faith in others. Yet the motives behind ... means of self-preservation, in order to protect themselves from feeling the pain of betrayal. ...
    (Date:1/24/2020)... ... January 24, 2020 , ... Devcool Inc ... today that it has completed its spin-off of HiPaaS, Inc ( http://www.hipaas.com ... while Devcool Inc continues its growth and focuses on Healthcare consulting services. ...
    Breaking Medicine News(10 mins):